Abstract
To date six bona fide death receptors (DRs) have been discovered and include tumor necrosis factor receptor 1 (TNF-R1), Fas, DR3, DR4, DR5 and DR6. Each receptor contains an extracellular region and an intracellular region; the intracellular region harbors a death domain that is critical for transduction of apoptotic signals. These death receptors are activated by their respective ligands. For example, TNFα activates TNF-R1 while FasL and TL1A activate Fas and DR3 respectively. TNF-related apoptosis inducing ligand (TRAIL), also known as Apo2L, activates DR4 and DR5. The ligand for DR6 has yet to be identified. These death receptors are also believed to be activated in a ligand-independent manner. A large body of recent evidence suggests that death receptors could be utilized as key molecular targets to develop novel therapeutics. This review discuses the pros and cons of targeting death receptors in the development of novel cancer therapeutic agents.
Keywords: Cancer Therapeutics, apoptotic
Call for Papers in Thematic Issues
Bioactive Polysaccharides From Natural Resources For Cancer Therapy
Bioactive polysaccharides from natural resources exhibit diverse therapeutic properties including anticancer, antioxidant, antidiabetic, immunostimulatory activity, and promotion of wound healing. In the past decades, most studies focused on the extraction and identification of polysaccharides, as well as their biological activities. A large number of bioactive polysaccharides with different structural features ...read more
Emerging Targets and Therapeutic Strategies in Modern Cancer Drug Development
This thematic issue focuses on hot and emerging areas in cancer drug targets, aiming to compile 10-12 high-quality articles that explore cutting-edge research, including but not limited to the discovery of novel targets, development of targeted therapeutics, clinical translation of promising strategies, and addressing challenges like drug resistance. It seeks ...read more
Integration of Single-Cell Multi-Omics and AI: Decoding Immune Cell State Transitions for Precision Therapeutic Targeting
The dynamic plasticity of immune cells within the tumor microenvironment is a pivotal determinant of cancer progression and treatment response. While transformative, single-cell multi-omics technologies (encompassing transcriptomics, epigenomics, proteomics, and spatial profiling) generate datasets of immense complexity. The true power of this data is unlocked through its systematic integration with ...read more
Molecular Targets and Emerging Therapies in Neuroblastoma
Neuroblastoma arises from the aberrant development of sympathetic neurons derived from the neural crest. Its pathogenesis remains unclear due to pronounced clinical, biological, and genetic heterogeneity. Despite advances in multimodal treatment, children with high-risk or advanced-stage neuroblastoma still face poor long-term survival. Moreover, intensive chemotherapy in early childhood often causes ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Current Drug Metabolism
Related Books
The Role of Nutraceuticals in Degenerative Diseases (Part 2)
Herb-Drug Interactions: A Medicinal Approach
The Role of Nutraceuticals in Degenerative Diseases (Part 1)
Brain Tumor Drug Development: Current Advances and Strategies (Part 2)
The Role of Asymmetric Synthesis in Drug Discovery
Brain Tumor Drug Development: Current Advances and Strategies (Part 1)
Handbook of Practical Pharmacology - I
Drug Repurposing for Antivirals
New Drugs Targeting Antibiotic-Resistant Bacteria: Recent Advances
Technical Advances in Pharmacy: An Overview
39